BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hashimoto A, Handa H, Hata S, Tsutaho A, Yoshida T, Hirano S, Hashimoto S, Sabe H. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer. Cell Commun Signal 2021;19:54. [PMID: 34001163 DOI: 10.1186/s12964-021-00733-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Liu Q, Cui M, Wang M, Hua S, Gao J, Liao Q. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma. Front Immunol 2021;12:774435. [PMID: 35046938 DOI: 10.3389/fimmu.2021.774435] [Reference Citation Analysis]
2 Schneider G, Wirth M, Keller U, Saur D. Rationale for MYC imaging and targeting in pancreatic cancer. EJNMMI Res 2021;11:104. [PMID: 34637026 DOI: 10.1186/s13550-021-00843-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]